CRISPR-Cpf1 RNP Complex Editing Gamma-Globin Promoter
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease and beta-thalassemia are inadequate, with long-term efficacy and safety of gene therapy unknown, and hematopoietic stem cell transplantation involving significant risks.
Innovation Solution
Development of genome editing systems using ribonucleoprotein (RNP) complexes, guide RNAs, Cpf1 proteins, and CRISPR-mediated methods to alter the promoter region of γ-globin genes, increasing expression of fetal hemoglobin (HbF).
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genome editing systems using RNP complexes and Cpf1 proteins are used to alter promoter regions of γ-globin genes, then fetal hemoglobin expression is increased, but the complexity of the treatment system increases
Solution Approach 1:
The treatment system is segmented into distinct functional modules: guide RNA molecules for target recognition, Cpf1 nuclease for DNA cleavage, and RNP complex for delivery. This segmentation allows each component to be optimized independently and facilitates the increased reliability through specialized function assignment while managing overall system complexity.
Solution Approach 2:
The patent introduces intermediary elements including guide RNA that mediates between the Cpf1 nuclease and the target DNA sequence, and RNP complexes that serve as intermediaries for delivering the editing system to hematopoietic stem cells. These intermediaries enable precise control of the genome editing process, improving treatment efficacy while providing structured pathways to manage system complexity.
2Reliability
If hematopoietic stem cell transplantation is used to treat sickle cell disease, then long-term cure is achieved, but significant risks including graft vs. host disease are introduced
Solution Approach 1:
The invention extracts and removes the harmful aspects of traditional transplantation by using genome editing to modify the patient's own hematopoietic stem cells ex vivo. This eliminates the need for allogeneic donor cells that cause graft vs. host disease, while still achieving long-term cure through corrected fetal hemoglobin production. The harmful foreign immune cells are taken out of the treatment paradigm entirely.
Solution Approach 2:
The treatment enables the patient's own cells to serve the therapeutic function through endogenous fetal hemoglobin production. By editing the patient's autologous hematopoietic stem cells to reactivate γ-globin genes, the system creates a self-sustaining therapeutic mechanism that produces fetal hemoglobin continuously without requiring ongoing external support or risking rejection, thus achieving long-term cure without graft vs. host disease.
3Ease of operation
If current treatments for sickle cell disease are used, then symptom management is provided, but long-term efficacy is inadequate
Solution Approach 1:
The invention applies preliminary action by performing ex vivo genome editing of hematopoietic stem cells before transplantation. The γ-globin genes are activated and fetal hemoglobin production is established in advance within the edited cells, ensuring long-term efficacy from the outset. This preliminary genetic modification prevents the progression to inadequate symptom management by creating a durable therapeutic effect that persists throughout the patient's lifetime.
Solution Approach 2:
The treatment fundamentally changes the biological parameter of hemoglobin composition by reactivating fetal hemoglobin production through genome editing. This parameter change from adult hemoglobin to fetal hemoglobin-containing red blood cells transforms the disease pathology, providing both ease of operation through natural physiological correction and reliable long-term efficacy by addressing the root genetic cause rather than merely managing symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach results in increased editing of target nucleic acids, potentially alleviating symptoms of sickle cell disease by enhancing HbF production, thus offering a more effective treatment option.
Implementation Method 1
genome editing systems using ribonucleoprotein (RNP) complexes, guide RNAs, Cpf1 proteins, and CRISPR-mediated methods to alter the promoter region of γ-globin genes
Data Source
AI summary
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.